- Zacks Small Cap Research•29 days ago
While several studies over the last number of years, including the widely cited Reddy et al and Wapner et al studies which have positively influenced reimbursement policy, have all indicated that chromosomal microarray analysis (CMA) is the preferred genetic testing modality versus karyotyping due to the former's proven greater accuracy, that it provides more substantive clinical information and is able to be used on fresh as well as preserved (i.e.
- Capital Cube•2 months ago
Click here to see latest analysisCombiMatrix Corp. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of CombiMatrix Corp. – Laboratory Corporation of America Holdings, Sequenom, Inc., Quest Diagnostics Incorporated and NeoGenomics, Inc. (LH-US, SQNM-US, DGX-US and NEO-US) that have also reported for this period.HighlightsSummary numbers: […] (Read more...) The post CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q1, 2016 By the Numbers appeared first on CapitalCube.
|Ask||4.60 x 200|
|52wk Range||2.62 - 24.60|
|Day's Range||3.14 - 3.85|
|Avg Vol (3m)||176,620|
As of 4:00 PM EDT. Market closed.